Tirzepatide vs Semaglutide (2026): Head-to-Head Clinical Data, Brands & Cost

Tirzepatide is the more potent compound. In the SURMOUNT-5 head-to-head trial published in the *New England Journal of Medicine* in May 2025, tirzepatide produced 20.2% mean weight loss vs 13.7% for semaglutide over 72 weeks. That is a real, direct, settled answer to the efficacy question.

Two 2026 approvals changed the picture. Wegovy HD (semaglutide 7.2 mg) was FDA-approved on March 19, 2026 with ~21% mean weight loss in the STEP UP trial — a result that approaches Zepbound territory. Wegovy pill (oral semaglutide 25 mg) was FDA-approved on December 22, 2025 and is the first-and-only oral GLP-1 for weight management, with ~17% mean weight loss in OASIS 4. So while the head-to-head data still favors tirzepatide, semaglutide now has more dose strengths, more formats, and a strong oral option that tirzepatide does not have.

On cost, both compounds now have direct-to-consumer cash programs. Zepbound through LillyDirect runs $299 for the 2.5 mg vial, $399 for the 5 mg vial, and $449/month for higher-dose vials with the Self Pay Journey program (as of February 2026). Wegovy through NovoCare runs $349/month for the standard injection, $399/month for Wegovy HD 7.2 mg, and $149–$299/month for the Wegovy pill. Insurance copay programs bring both down to as little as $25/month for commercially covered patients.

For research-use contexts, semaglutide and tirzepatide compounds are often much cheaper than cash-pay prescription programs; the relevant supplier links are in the supplies section below.

Most of the SERP confusion lives here. People search "is Wegovy semaglutide or tirzepatide," "difference between Zepbound and Wegovy," and "Ozempic vs Mounjaro" because the brand names do not signal the active ingredient. Here is the full 2026 brand map.

The single most useful clarification: same molecule, different brand for different uses. Ozempic, Rybelsus, Wegovy, Wegovy HD, and Wegovy pill all contain semaglutide — Novo Nordisk simply markets it under different brand names for different indications, formats, and doses. Mounjaro and Zepbound both contain tirzepatide — Eli Lilly markets it as Mounjaro for T2D and as Zepbound for weight management and OSA.

Until May 2025, every "tirzepatide vs semaglutide" comparison was cross-trial — meaning the two compounds had never been studied side-by-side in the same patient population. SURMOUNT-5 changed that. Below is the full efficacy picture from the Phase 3 trials that actually matter for this comparison.

What SURMOUNT-5 actually proved. Same protocol, same 72-week duration, same titration rules, 751 adults randomized 1:1. Tirzepatide at max tolerated dose produced 20.2% mean weight loss vs 13.7% for semaglutide at max tolerated dose. That is a 6.5 percentage-point absolute gap, or roughly 47% more relative weight reduction on tirzepatide. Waist circumference also dropped more on tirzepatide (-18.4 cm vs -13.0 cm). 19.7% of tirzepatide patients hit ≥30% weight loss vs 6.9% on semaglutide. This is the most important single data point in the comparison.

What STEP UP added in 2026. Higher-dose semaglutide (7.2 mg, the Wegovy HD dose) produced ~21% mean weight loss in adults with obesity without diabetes — a result that approaches Zepbound's 20.2% in SURMOUNT-5. STEP UP was not a head-to-head trial against tirzepatide, so the comparison is cross-trial and not as clean as SURMOUNT-5, but the practical implication is real: a patient who tolerates semaglutide well and goes to Wegovy HD now has access to weight-loss numbers that previously required tirzepatide.

I verified the SURMOUNT-5 efficacy numbers against the *NEJM* paper (DOI: 10.1056/NEJMoa2416394, May 2025) and the STEP UP 20.7% figure against the Novo Nordisk FDA approval press release and the Pharmacy Times STEP UP summary. The Wegovy HD figure is reported across multiple primary sources at ~21% on the trial-product estimand and ~19% on the treatment-policy estimand.

Both drugs work by activating receptors for gut hormones that help control appetite and blood sugar. The difference is how many receptors each one activates.

Semaglutide activates one receptor: the GLP-1 receptor. GLP-1 is a hormone your gut releases when you eat. It slows how fast food leaves your stomach, makes you feel full sooner, tells your pancreas to release insulin when blood sugar is high, and reduces glucagon (another hormone that raises blood sugar). That single mechanism is why semaglutide is effective for both weight loss and type 2 diabetes.

Tirzepatide activates two receptors: GLP-1 and GIP. GIP is a second gut hormone. Adding GIP activation on top of GLP-1 is the mechanism behind tirzepatide's efficacy advantage in SURMOUNT-5. The SURMOUNT-5 authors hypothesize that GIP receptor expression in brain regions that regulate food intake doesn't fully overlap with GLP-1 receptor expression, which may explain why the dual mechanism produces additive — not redundant — effects on weight loss.

The shorthand: semaglutide reduces calories in. Tirzepatide reduces calories in *and* changes how those calories are metabolized. The third receptor (glucagon) is added in retatrutide — investigational, not yet FDA-approved.

Two FDA approvals reshape the 2026 picture for semaglutide. Most older comparison articles do not yet reflect them.

Wegovy HD was FDA-approved on March 19, 2026 under the Commissioner's National Priority Voucher accelerated review pilot. The pivotal trial was STEP UP, a 72-week Phase 3b trial in 1,407 adults with obesity (BMI ≥30) without diabetes, randomized 5:1:1 to semaglutide 7.2 mg, 2.4 mg, or placebo. Mean weight loss was ~21% on 7.2 mg vs ~15.6% on 2.4 mg vs ~3.9% on placebo. About one-third of patients on 7.2 mg achieved ≥25% body weight reduction.

The clinically important new signal in STEP UP: dysesthesia. Altered skin sensation (described as sensitivity, tingling, or burning without obvious cause) occurred in 22.9% of patients on 7.2 mg vs 6.0% on 2.4 mg vs 0.5% on placebo. The FDA labeled this for further investigation. Symptoms generally resolved spontaneously or with dose reduction.

Wegovy pill was FDA-approved on December 22, 2025 and launched in the US in early January 2026. It is the first and only oral GLP-1 receptor agonist approved specifically for chronic weight management. The pivotal trial was OASIS 4, a 64-week Phase 3b trial in 307 adults with obesity or overweight plus at least one weight-related comorbidity. Mean weight loss was 16.6% on-treatment and 13.6% on the treatment-policy estimand — roughly equivalent to the injectable Wegovy 2.4 mg dose. Wegovy pill is taken once daily on an empty stomach with a 30-minute waiting period before eating.

Importantly, this is a different product than Rybelsus. Rybelsus is approved for type 2 diabetes (oral semaglutide 3, 7, or 14 mg). Wegovy pill is approved for weight management and is a higher dose (25 mg). The marketing brand and the FDA-approved indication are different even though the underlying compound is the same.

What this means for the comparison. As of May 2026, tirzepatide does not have an FDA-approved oral formulation. Eli Lilly's investigational oral non-peptide GLP-1, orforglipron, was approved April 1, 2026 (branded Foundayo) but it is a different molecule, not tirzepatide. If oral dosing is a hard requirement — say, for needle-averse patients, travel logistics, or insurance reasons — semaglutide is currently the only FDA-approved option for weight management.

Both drugs produce the same underlying GI side-effect pattern — nausea, diarrhea, vomiting, constipation — because they both slow gastric emptying and activate brainstem pathways that regulate nausea. What varies is the incidence by dose and, in the case of Wegovy HD, the appearance of a new signal.

Class-wide warnings that apply to both drugs. Both Wegovy and Zepbound carry boxed warnings for thyroid C-cell tumors (a signal seen in rodent studies; never confirmed in humans). Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both carry precautions for acute pancreatitis, gallbladder events, and diabetic retinopathy progression in patients with existing retinopathy.

Practical takeaway on tolerability. SURMOUNT-5 showed comparable tolerability profiles between max-dose tirzepatide and max-dose semaglutide on the standard GI side effects. The Wegovy HD dysesthesia rate is high enough that it is a real consideration for anyone choosing the 7.2 mg dose specifically. Class warnings apply to both compounds regardless of which one you choose.

Both drugs use a slow upward titration to manage GI side effects. The schedules are not interchangeable.

The Wegovy pill timing rule matters. Oral semaglutide bioavailability is heavily dependent on dosing on an empty stomach with no more than 4 ounces of plain water, then waiting at least 30 minutes before food, drinks, or other medications. Adherence to that window is the single biggest factor in whether the oral form actually delivers the on-trial efficacy. Patients who cannot reliably fast that window may be better served by an injectable.

Missed doses. For weekly injectables (Wegovy, Wegovy HD, Zepbound, Mounjaro), the FDA labels allow catch-up dosing within a defined window (check the current prescribing information; the window has been revised across label updates). If you miss the window, skip the dose and resume the next scheduled dose — do not double up.

Both Lilly and Novo Nordisk cut cash-pay pricing aggressively in late 2025 and early 2026. The list price of both drugs is still about $1,086 (Zepbound) and $1,349 (Wegovy) per month, but almost nobody actually pays that anymore.

Practical takeaway. For most people without insurance coverage for the brand, the cheapest legitimate option for tirzepatide is LillyDirect vials at $299–$449/month and the cheapest legitimate option for semaglutide is NovoCare, where the Wegovy pill 1.5 mg dose is $149/month and the standard Wegovy injection is $349/month. Both manufacturer programs require a valid prescription. Self-pay pricing on the Lilly side requires you to use single-dose vials and draw with a syringe yourself — the pre-filled KwikPen is at a separate price point.

This is not a recommendation. It is a framework for understanding the tradeoffs. The right answer for any individual patient depends on medical history, insurance coverage, prescriber assessment, and personal preferences a webpage cannot evaluate.

When efficacy alone is not the deciding factor. Insurance coverage, dosing format (injection vs pill), tolerability history, OSA comorbidity, and cost can all reasonably outweigh the SURMOUNT-5 efficacy gap. A patient who can't afford Zepbound at LillyDirect prices but has $25 Wegovy copay coverage will get better real-world outcomes on Wegovy than on theoretical Zepbound they can't fill consistently.

Switching between compounds is clinically common and routinely managed by prescribers, but it requires a fresh titration. Do not switch without professional guidance.

Common switches include Ozempic → Mounjaro (T2D, same indication, switch for efficacy), Wegovy → Zepbound (weight management, same indication, switch for efficacy), Wegovy → Wegovy HD (within-class escalation when 2.4 mg has plateaued), and Wegovy injection → Wegovy pill (switch for format preference when efficacy is acceptable at the standard dose).

Tirzepatide and semaglutide are both available from research-peptide suppliers as lyophilized powders that the buyer reconstitutes with bacteriostatic water. Per-mg pricing is much lower than pharmacy, but the trade-offs are significant: no clinical oversight, no pharmacy-grade quality assurance, no insurance, FDA enforcement on compounding has tightened in 2026, and quality verification falls entirely on the buyer.

We do not treat the research-market path as competitive with the LillyDirect or NovoCare pathways for FDA-approved use cases. The cash-pay floor on both compounds is now low enough — $149/month for Wegovy pill, $299/month for Zepbound 2.5 mg vials — that the historical "research-market is much cheaper" argument has narrowed substantially. For supplier context on the broader research-peptide landscape, see our supplier directory, the Best Grey-Market Peptide Suppliers review, and the How to Read a Peptide COA guide.

If sourcing through the research market, the quality-verification step is not optional. The GLP-1 class is the most counterfeited peptide category on the internet because demand is high and legitimate manufacturing is expensive. Both Peptide Partners and Pivot Labs maintain published third-party testing data (Finnrick) on GLP-1 inventory, which is the minimum bar to even consider a supplier in this category.